Compare AbCellera Biologics Inc (ABCL) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ascendis Pharma A/S — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Ascendis Pharma A/S trades at $274.27 (market cap $17.51B). The key difference: Ascendis Pharma A/S is far larger — about 7.5× AbCellera Biologics Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | ASND | |
|---|---|---|
Market Cap | $2.35B | $17.51B |
Sector | Health | Health |
52-Week High | $8.12 | $274.50 |
52-Week Low | $2.78 | $163.32 |
Enterprise Value | $1.99B | $17.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Ascendis Pharma (ASND) trades at $266.97, down 2.74% on the day. The stock maintains a bullish technical outlook with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth is strong, reaching $720.13M in 2025, but the company remains unprofitable with a net loss of $228.03M. Recent positive clinical trial data for TransCon CNP and inclusion in Russell indexes highlight ongoing business momentum.
The outlook is optimistic, driven by analyst consensus and a $320 price target, but risks include persistent losses, high debt levels, and reliance on pipeline success. Near-term performance hinges on Q2 2026 earnings versus the $1.29 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
